

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Single Technology Appraisal**


# Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

### **Final Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
Blueprint Medicines (avapritinib)	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
Patient/carer groups	Allied Health Professionals Federation
<ul><li>African Caribbean Leukaemia Trust</li><li>Anthony Nolan</li></ul>	Board of Community Health Councils in Wales
Black Health Agency for Equality	British National Formulary
Blood Cancer UK	Care Quality Commission
Cancer Black Care	Department of Health - Northern Ireland
Cancer52	Healthcare Improvement Scotland
Chronic Lymphocytic Leukaemia     Support Association	Hospital Information Services - Jehovah's Witnesses
Chronic Myeloid Leukaemia Support Group	Medicines and Healthcare products     Regulatory Agency
Independent Cancer Patients Voice	National Association of Primary Care
Kevin Kararwa Leukaemia Trust	National Pharmacy Association
Leukaemia Cancer Society	NHS Blood and Transplant
Leukaemia Care	NHS Confederation
Lymphoma Action	NHS Wales Joint Commissioning
Macmillan Cancer Support	Committee
Maggie's Centres	Scottish Medicines Consortium
Marie Curie	Welsh Government
MPN Voice	
<ul> <li>South Asian Health Foundation</li> </ul>	Comparator companies
Specialised Healthcare Alliance	None
Tenovus Cancer Care	Polovent research groups
UK Mastocytosis support group	<ul><li>Relevant research groups</li><li>Cochrane Haematological Malignancies Group</li></ul>
	Genomics England
Healthcare professional groups	Institute of Cancer Research
Association of Cancer Physicians	Leukaemia Busters
Association of Genetic Nurses and	Leukaemia UK
Counsellors	MRC Clinical Trials Unit
British Association of Dermatologists	National Institute for Health Research
British Blood Transfusion Society	
British Geriatrics Society	Associated Public Health groups

Final stakeholder list for the evaluation of avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

Issue date: September 2025



37	Public Health Wales JK Health Security Agency
Immunology  British Society for Genetic Medicine  British Society for Haematology  British Society for Immunology  British Society of Interventional Radiology  Cancer Research UK  Joint Committee on Immunology and Allergy  Royal College of General Practitioners  Royal College of Nursing  Royal College of Pathologists  Royal College of Physicians  Royal College of Radiologists  Royal College of Radiologists  Royal Pharmaceutical Society  Royal Society of Medicine  Society and College of Radiographers  UK Clinical Pharmacy Association  UK Oncology Nursing Society  Others  Department of Health and Social Care  NHS England	Six Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


#### **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final stakeholder list for the evaluation of avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

Issue date: September 2025





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.